Giorgia Saia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Giorgia Saia has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Bedogni
University of Padua
10 shared publications - Giordana Bettini
University-Hospital of Padova
7 shared publications - Giuseppina Campisi
University of Palermo
4 shared publications - Olga Di Fede
Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
3 shared publications - Vittorio Fusco
Department of Medicine, Oncology Unit, University Hospital “SS. Antonio E Biagio E C. Arrigo”, Alessandria, Italy
3 shared publications - Giorgio Bedogni
Department of Medical and Surgical Sciences Alma Mater Studiorum‐University of Bologna Bologna Italy
2 shared publications
Latest Publications
- 1 October 2024
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 32 (10) , 1-3
Letter to editor regarding “bone modifying agents in breast cancer patients as adjuvant therapy and prevention of cancer treatment-induced bone loss (CTIBL): Evaluation of risk of medication-related osteonecrosis of the jaw (MRONJ)”
- 1 October 2024
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 32 (10) , 1-3
Letter to editor regarding “bone modifying agents in breast cancer patients as adjuvant therapy and prevention of cancer treatment-induced bone loss (CTIBL): Evaluation of risk of medication-related osteonecrosis of the jaw (MRONJ)”
- Open Access
- 8 May 2023
- Published by Qeios Ltd in Qeios Preprints
Low Donor Site Morbidity Supports the Use of Infraumbilical Flaps for Head and Neck Reconstruction: A Retrospective Cohort Study
Background: Currently, the standard design of the skin component of abdominal soft-tissue flaps recommended for head and neck reconstruction encompasses the upper and lower periumbilical region to include the maximum number of myocutaneous perforators. Yet, this flap design precludes the harvest of bilateral flaps and the use of the contralateral area in case of flap failure. Aim: We aimed at proving the long-term safety of infraumbilical abdominal free flaps in terms of abdominal wall integrity. Methods: Consecutive subjects who underwent reconstruction of composite cervico-facial defects with infraumbilical free flaps between 2008 - 2020 were enrolled. After surgery, patients were followed up at three-month intervals to evaluate the incidence of any complications at the donor site. Results: 25 patients underwent reconstruction with free flaps from the lower abdomen. A total of 35 abdominal flaps were performed; ten patients underwent bilateral flap harvest. Marginal abdominal skin necrosis occurred in 3 patients. Abdominal bulge occurred in one case; neither hernia nor abdominal wall weakness was encountered at a median follow-up of 12 months. Conclusions: The infraumbilical region is a safe donor area of free flaps for head and neck reconstruction that preserves abdominal wall firmness and provides a satisfactory cosmetic result at the donor site.
- 8 May 2023
- Published by Qeios Ltd in Qeios Preprints
Open AccessLow Donor Site Morbidity Supports the Use of Infraumbilical Flaps for Head and Neck Reconstruction: A Retrospective Cohort Study
Background: Currently, the standard design of the skin component of abdominal soft-tissue flaps recommended for head and neck reconstruction encompasses the upper and lower periumbilical region to include the maximum number of myocutaneous perforators. Yet, this flap design precludes the harvest of bilateral flaps and the use of the contralateral area in case of flap failure. Aim: We aimed at proving the long-term safety of infraumbilical abdominal free flaps in terms of abdominal wall integrity. Methods: Consecutive subjects who underwent reconstruction of composite cervico-facial defects with infraumbilical free flaps between 2008 - 2020 were enrolled. After surgery, patients were followed up at three-month intervals to evaluate the incidence of any complications at the donor site. Results: 25 patients underwent reconstruction with free flaps from the lower abdomen. A total of 35 abdominal flaps were performed; ten patients underwent bilateral flap harvest. Marginal abdominal skin necrosis occurred in 3 patients. Abdominal bulge occurred in one case; neither hernia nor abdominal wall weakness was encountered at a median follow-up of 12 months. Conclusions: The infraumbilical region is a safe donor area of free flaps for head and neck reconstruction that preserves abdominal wall firmness and provides a satisfactory cosmetic result at the donor site.
- Open Access
- 27 March 2023
- Published by Qeios Ltd in Qeios Preprints
Italian Position Paper (SIPMO-SICMF) on Medication-Related Osteonecrosis of the Jaw (MRONJ)
Despite being one of the most recently studied oral diseases, MRONJ remains a condition with uncertain and controversial issues. The aim of this updated version of the position paper on MRONJ developed by the Italian Societies of Oral Pathology and Medicine (SIPMO) and of Maxillofacial Surgery (SICMF) is to set forth an original interpretation of the current disputes on MRONJ. The Expert panel was appointed by the SIPMO and SICMF Board of Trustees in 2010 and comprised a multidisciplinary group of clinicians and researchers with recognized expertise in the field, who tracked the available literature and released two consecutive sets of Italian recommendations on MRONJ in 2013 and 2020. The advance of scientific knowledge and the perceived need for refinements to the previous position papers were recognized by the board panel who approved the submission of this updated version. This position paper highlights the current research status and provides a different perspective on several debated aspects of MRONJ including risk estimates, disease definition, diagnostic pathway, individual risk assessment, and the fundamental role of imaging in the diagnosis, classification, and management of MRONJ. The SIPMO-SICMF expert panel believes essential for the information provided to be disseminated to healthcare providers and patients at increased MRONJ risk. The SIPMO-SICMF Expert Panel recognizes that the statements and recommendations here provided warrant further confirmation and updates and highlight the need for a global and interdisciplinary scientific approach to MRONJ to overcome region-specific challenges.
- 27 March 2023
- Published by Qeios Ltd in Qeios Preprints
Open AccessItalian Position Paper (SIPMO-SICMF) on Medication-Related Osteonecrosis of the Jaw (MRONJ)
Despite being one of the most recently studied oral diseases, MRONJ remains a condition with uncertain and controversial issues. The aim of this updated version of the position paper on MRONJ developed by the Italian Societies of Oral Pathology and Medicine (SIPMO) and of Maxillofacial Surgery (SICMF) is to set forth an original interpretation of the current disputes on MRONJ. The Expert panel was appointed by the SIPMO and SICMF Board of Trustees in 2010 and comprised a multidisciplinary group of clinicians and researchers with recognized expertise in the field, who tracked the available literature and released two consecutive sets of Italian recommendations on MRONJ in 2013 and 2020. The advance of scientific knowledge and the perceived need for refinements to the previous position papers were recognized by the board panel who approved the submission of this updated version. This position paper highlights the current research status and provides a different perspective on several debated aspects of MRONJ including risk estimates, disease definition, diagnostic pathway, individual risk assessment, and the fundamental role of imaging in the diagnosis, classification, and management of MRONJ. The SIPMO-SICMF expert panel believes essential for the information provided to be disseminated to healthcare providers and patients at increased MRONJ risk. The SIPMO-SICMF Expert Panel recognizes that the statements and recommendations here provided warrant further confirmation and updates and highlight the need for a global and interdisciplinary scientific approach to MRONJ to overcome region-specific challenges.
- Open Access
Temporary Denosumab Discontinuation Promotes Bone Healing of Osteonecrosis of the Jaw and Minimizes the Invasiveness of Surgery: A Case Presentation
Denosumab has proved effective at low doses in increasing bone mineral density in osteoporosis patients. In contrast to high-doses antiresorptive therapy, denosumab has a transient effect on the inhibition of the bone remodeling process, suggesting that denosumab-related osteonecrosis is a self-limiting disease, with a high curative potential of surgery when performed after a proper duration of receptor activator of nuclear factor-kB ligand (RANKL) inhibitor suspension. We report the long-term clinical and radiological (Computed Tomography—CT scan) data of a patient affected by secondary osteoporosis (cancer treatment-induced bone loss—CTIBL for metastatic breast cancer) who underwent surgical treatment for stage II denosumab-related osteonecrosis of the upper maxilla 7 months after denosumab suspension. A minimally invasive approach was performed with the extraction of the first right upper molar and debridement of the surrounding alveolar bone. After surgery, the patient was followed up at three-month intervals up to 1 year, and clinical and radiological data (CT scan) were recorded at each follow-up for the early detection of signs of recurrent disease. The mucosal healing remained stable in the long term, with radiological signs of bone remodeling in the post-operative site since the 6-month follow-up. The presented case strengthens the hypothesis that denosumab induces temporary alterations of bone turnover with a predictable curative effect of minimal surgical procedures in cases of denosumab-related osteonecrosis of the jaw.
Open AccessTemporary Denosumab Discontinuation Promotes Bone Healing of Osteonecrosis of the Jaw and Minimizes the Invasiveness of Surgery: A Case Presentation
Denosumab has proved effective at low doses in increasing bone mineral density in osteoporosis patients. In contrast to high-doses antiresorptive therapy, denosumab has a transient effect on the inhibition of the bone remodeling process, suggesting that denosumab-related osteonecrosis is a self-limiting disease, with a high curative potential of surgery when performed after a proper duration of receptor activator of nuclear factor-kB ligand (RANKL) inhibitor suspension. We report the long-term clinical and radiological (Computed Tomography—CT scan) data of a patient affected by secondary osteoporosis (cancer treatment-induced bone loss—CTIBL for metastatic breast cancer) who underwent surgical treatment for stage II denosumab-related osteonecrosis of the upper maxilla 7 months after denosumab suspension. A minimally invasive approach was performed with the extraction of the first right upper molar and debridement of the surrounding alveolar bone. After surgery, the patient was followed up at three-month intervals up to 1 year, and clinical and radiological data (CT scan) were recorded at each follow-up for the early detection of signs of recurrent disease. The mucosal healing remained stable in the long term, with radiological signs of bone remodeling in the post-operative site since the 6-month follow-up. The presented case strengthens the hypothesis that denosumab induces temporary alterations of bone turnover with a predictable curative effect of minimal surgical procedures in cases of denosumab-related osteonecrosis of the jaw.
- 1 January 2021
- Published by Elsevier in Oral Oncology
- Vol. 112, 105073
Safety of boneless reconstruction of the mandible with a CAD/CAM designed titanium device: The replica cohort study
- 1 January 2021
- Published by Elsevier in Oral Oncology
- Vol. 112, 105073
Safety of boneless reconstruction of the mandible with a CAD/CAM designed titanium device: The replica cohort study
- Open Access
- 29 July 2018
- Published by Qeios Ltd in Qeios Preprints
Exposure to antiresorptive therapy with bisphosphonates does not induce histological changes in human alveolar jawbone
Aim: The identification of specific alterations in the alveolar jawbone of patients treated with nitrogen-containing bisphosphonates (NBP) but without bisphosphonate-related osteonecrosis of the jaw (BRONJ) may help to identify the early steps of BRONJ and to select patients at risk for it. Materials and Methods: We performed a case-control study. Cases were 60 individuals treated with NBP without clinical and radiological signs of BRONJ and requiring surgical tooth extraction. Controls were 60 individuals never treated with NBP and requiring tooth extraction. Cases and controls were matched by sex (same) and age (within 5 years). 18 categorical (basophile reversal lines, osteoblasts, osteoblastic lines, osteocytes, empty osteocytic lacunae, osteoclasts, Howship’s lacunae, vessel dilatation, vascular congestion, arteriolar thickening, intravascular fat globules, calcific fat necrosis, fatty bone marrow, ruptured adipocytes, granular cytoplasm of adipocytes, oil cysts, perivascular fibrosis, diffuse fibrous metaplasia) and 2 ordinal histopathological variables (inflammation and bone maturation) were investigated. Exact univariable and multivariable (correction for gender and age) logistic regression was used to test the association between NBP use and the histopathological variables. Because of multiple comparisons, the critical p-value was set to 0.0025 (0.05/20). Results: Cases and controls did not differ for any study variable except for vascular congestion that was significantly associated with NBP use (multivariable OR = 0.24, exact 95% CI 0.10 to 0.57 for cases vs. controls, p = 0.0006). Conclusions: Use of NBP does not produce specific histological alveolar bone alterations in the absence of overt BRONJ disease.
- 29 July 2018
- Published by Qeios Ltd in Qeios Preprints
Open AccessExposure to antiresorptive therapy with bisphosphonates does not induce histological changes in human alveolar jawbone
Aim: The identification of specific alterations in the alveolar jawbone of patients treated with nitrogen-containing bisphosphonates (NBP) but without bisphosphonate-related osteonecrosis of the jaw (BRONJ) may help to identify the early steps of BRONJ and to select patients at risk for it. Materials and Methods: We performed a case-control study. Cases were 60 individuals treated with NBP without clinical and radiological signs of BRONJ and requiring surgical tooth extraction. Controls were 60 individuals never treated with NBP and requiring tooth extraction. Cases and controls were matched by sex (same) and age (within 5 years). 18 categorical (basophile reversal lines, osteoblasts, osteoblastic lines, osteocytes, empty osteocytic lacunae, osteoclasts, Howship’s lacunae, vessel dilatation, vascular congestion, arteriolar thickening, intravascular fat globules, calcific fat necrosis, fatty bone marrow, ruptured adipocytes, granular cytoplasm of adipocytes, oil cysts, perivascular fibrosis, diffuse fibrous metaplasia) and 2 ordinal histopathological variables (inflammation and bone maturation) were investigated. Exact univariable and multivariable (correction for gender and age) logistic regression was used to test the association between NBP use and the histopathological variables. Because of multiple comparisons, the critical p-value was set to 0.0025 (0.05/20). Results: Cases and controls did not differ for any study variable except for vascular congestion that was significantly associated with NBP use (multivariable OR = 0.24, exact 95% CI 0.10 to 0.57 for cases vs. controls, p = 0.0006). Conclusions: Use of NBP does not produce specific histological alveolar bone alterations in the absence of overt BRONJ disease.
- 27 May 2016
- Published by Wiley in Oral Diseases
- Vol. 22 (6) , 543-548
BRONJ in patients with rheumatoid arthritis: a multicenter case series
Objective: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of various medications (bisphosphonates, anti‐resorptive, and anti‐angiogenic drugs). ONJ pathogenesis is still unclear although some risk factors have been recognized. Of these, rheumatoid arthritis (RA) has been hypothesized as a potential risk factor for developing ONJ. This observational study will describe a multicenter case series of patients affected with RA and ONJ, and it will attempt to evaluate the association between features of ONJ and pharmacological, systemic, and site variables.Methods: Demographic, pharmacological, and clinical data from 18 RA patients with ONJ were collected and registered from three Italian centers (i.e., Palermo, Verona, and Padua) from 2004 to 2013.Results: Sixteen (88.9%) patients were in therapy for RA: 9 of 18 (50.0%) with systemic steroids, 3 of 18 (16.7%) with methotrexate, and 4 of 18 (22.2%) with both medications. Two patients were not receiving treatment for RA. All patients took NBPs for secondary osteoporosis (average NBP duration of 69 months, range: 20–130): Fifteen (83.3%) patients were treated with single NBPs, while three (16.7%) with different molecules; one patient was also treated with denosumab. Mandible was affected more frequently (66.7%) than maxilla (33.3%); one patient presented multiple ONJ events.Conclusions: This is the first multicenter case series in the international literature regarding our topic. Focusing on our data, it could be hypothesized that patients with RA may be more susceptible to ONJ than the majority of osteometabolic patients. In our opinion, it could be important to monitor also denosumab or other biological drug side effects.
- 27 May 2016
- Published by Wiley in Oral Diseases
- Vol. 22 (6) , 543-548
BRONJ in patients with rheumatoid arthritis: a multicenter case series
Objective: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of various medications (bisphosphonates, anti‐resorptive, and anti‐angiogenic drugs). ONJ pathogenesis is still unclear although some risk factors have been recognized. Of these, rheumatoid arthritis (RA) has been hypothesized as a potential risk factor for developing ONJ. This observational study will describe a multicenter case series of patients affected with RA and ONJ, and it will attempt to evaluate the association between features of ONJ and pharmacological, systemic, and site variables.Methods: Demographic, pharmacological, and clinical data from 18 RA patients with ONJ were collected and registered from three Italian centers (i.e., Palermo, Verona, and Padua) from 2004 to 2013.Results: Sixteen (88.9%) patients were in therapy for RA: 9 of 18 (50.0%) with systemic steroids, 3 of 18 (16.7%) with methotrexate, and 4 of 18 (22.2%) with both medications. Two patients were not receiving treatment for RA. All patients took NBPs for secondary osteoporosis (average NBP duration of 69 months, range: 20–130): Fifteen (83.3%) patients were treated with single NBPs, while three (16.7%) with different molecules; one patient was also treated with denosumab. Mandible was affected more frequently (66.7%) than maxilla (33.3%); one patient presented multiple ONJ events.Conclusions: This is the first multicenter case series in the international literature regarding our topic. Focusing on our data, it could be hypothesized that patients with RA may be more susceptible to ONJ than the majority of osteometabolic patients. In our opinion, it could be important to monitor also denosumab or other biological drug side effects.
- Open Access
- 1 September 2014
- Published by Elsevier in British Journal of Oral and Maxillofacial Surgery
- Vol. 52 (7) , 603-608
Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease
- 1 September 2014
- Published by Elsevier in British Journal of Oral and Maxillofacial Surgery
- Vol. 52 (7) , 603-608
Open AccessStaging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease
- 1 April 2006
- Published by Georg Thieme Verlag KG in Journal of Reconstructive Microsurgery
- Vol. 22 (03) , A092
Application of Internal Fixation and Principles for the Stabilization of Vascularized Bone in Head and Neck Reconstruction: A 15-Year Experience
Primary or delayed reconstruction of extensive jawbone defects with vascularized bone is the standard treatment when vascular insufficiency of the recipient area coexists. Stable internal fixation of vascularized bone segments is crucial to achieve prompt bone healing and to hasten functional rehabilitation. Shaping and fixation of the vascularized bone allow for precise fitting of the defect and provide very reasonable asthetic and functional results. Different load–bearing and load–sharing fixation systems have been developed and evolved during the last two decades. Traditional load–bearing systems applied to mandibular reconstruction offer the advantage of rigid fixation and allow for masticatory load early and safely. However, they are heavy systems that can compress the periosteum and reduce the vascularization of bone segments. Furthermore, plate removal is often necessary and requires an additional surgical procedure under general anesthesia. In recent years, new load–bearing systems have been developed, which are much lighter than the former ones, easy to shap, and do not compress the bone. Load–sharing systems (micro and mini plates and screws) have also been developed and extensively used in reconstructive surgery of the head and neck. These systems share the load–bearing with the bone, and they do not allow for early mastication until complete bone union has been achieved. Temporary intermaxillary fixation has to be added in some cases to ensure adequate stability during the healing phase. However, mini and micro plates are easy to handle and to insert, as well as to remove, if necessary. Number and size of the plates and screws used to fix the bone segments depend largely on the defect size and location. The authors presented their current protocol of internal fixation of vascularized bone based on a 15-year experience in jaw reconstruction and more than 100 free bone flaps.
- 1 April 2006
- Published by Georg Thieme Verlag KG in Journal of Reconstructive Microsurgery
- Vol. 22 (03) , A092
Application of Internal Fixation and Principles for the Stabilization of Vascularized Bone in Head and Neck Reconstruction: A 15-Year Experience
Primary or delayed reconstruction of extensive jawbone defects with vascularized bone is the standard treatment when vascular insufficiency of the recipient area coexists. Stable internal fixation of vascularized bone segments is crucial to achieve prompt bone healing and to hasten functional rehabilitation. Shaping and fixation of the vascularized bone allow for precise fitting of the defect and provide very reasonable asthetic and functional results. Different load–bearing and load–sharing fixation systems have been developed and evolved during the last two decades. Traditional load–bearing systems applied to mandibular reconstruction offer the advantage of rigid fixation and allow for masticatory load early and safely. However, they are heavy systems that can compress the periosteum and reduce the vascularization of bone segments. Furthermore, plate removal is often necessary and requires an additional surgical procedure under general anesthesia. In recent years, new load–bearing systems have been developed, which are much lighter than the former ones, easy to shap, and do not compress the bone. Load–sharing systems (micro and mini plates and screws) have also been developed and extensively used in reconstructive surgery of the head and neck. These systems share the load–bearing with the bone, and they do not allow for early mastication until complete bone union has been achieved. Temporary intermaxillary fixation has to be added in some cases to ensure adequate stability during the healing phase. However, mini and micro plates are easy to handle and to insert, as well as to remove, if necessary. Number and size of the plates and screws used to fix the bone segments depend largely on the defect size and location. The authors presented their current protocol of internal fixation of vascularized bone based on a 15-year experience in jaw reconstruction and more than 100 free bone flaps.